Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Sentiment | Market Cap | Shares | Institutional % | Insider % | Net Insider (L12M) | Net Insider (L3M) |
|---|---|---|---|---|---|---|---|---|---|
| ONC | BEONE MEDICINES LTD | $35.48B | 1,438,553,263 | 2.29% | 32.05% | Net Buying | Net Selling | ||
| NVO | NOVO NORDISK A S | $244.88B | 4,443,500,000 | 6.76% | 0.00% | ||||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $52.56B | 132,113,818 | 82.79% | 17.21% | Net Selling | Net Selling | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $3.11B | 75,795,759 | 53.90% | 9.39% | Net Selling | Net Selling | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $469.52M | 56,297,535 | 70.82% | 22.18% | Net Selling | Net Selling | ||
| CORT | CORCEPT THERAPEUTICS INC | $3.68B | 105,188,217 | 28.42% | 71.58% | Net Buying | Net Buying | ||
| VCEL | VERICEL CORP | $1.88B | 50,574,026 | 91.18% | 8.82% | Net Selling | Net Selling | ||
| ARGX | ARGENX SE | $48.88B | 61,034,202 | 50.00% | 0.00% | ||||
| KRYS | KRYSTAL BIOTECH INC | $7.10B | 28,997,519 | 79.21% | 20.79% | Net Selling | Net Selling | ||
| TECH | BIO-TECHNE CORP | $9.82B | 155,812,701 | 97.61% | 2.39% | Net Buying | Net Selling | ||
| GMAB | GENMAB A | $20.42B | 64,206,349 | 96.17% | 0.00% | ||||
| ABEO | ABEONA THERAPEUTICS INC | $282.88M | 54,191,361 | 45.75% | 54.25% | Net Selling | Net Selling | ||
| ADMA | ADMA BIOLOGICS INC | $4.29B | 237,997,765 | 79.67% | 20.33% | Net Selling | Net Selling | ||
| XOMA | XOMA ROYALTY CORP | $329.64M | 12,383,103 | 18.93% | 81.07% | Net Selling | Net Buying | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $2.02B | 131,840,559 | 49.82% | 12.61% | Net Buying | Net Selling | ||
| VCYT | VERACYTE INC | $3.45B | 79,049,173 | 67.83% | 32.17% | Net Selling | Net Selling | ||
| LGND | LIGAND PHARMACEUTICALS INC | $3.78B | 19,681,720 | 18.29% | 81.71% | Net Selling | Net Selling | ||
| CRMD | CORMEDIX INC | $960.44M | 78,789,045 | 54.72% | 8.62% | Net Selling | Net Selling | ||
| MNKD | MANNKIND CORP | $1.73B | 307,070,281 | 35.49% | 64.51% | Net Selling | Net Selling | ||
| NAGE | NIAGEN BIOSCIENCE INC | $514.75M | 79,806,139 | 18.41% | 81.59% | Net Buying | Net Buying | ||
| RPRX | ROYALTY PHARMA PLC | $22.89B | 577,238,107 | 56.76% | 17.33% | Net Selling | Net Selling | ||
| EXEL | EXELIXIS INC | $11.37B | 268,112,157 | 93.47% | 5.23% | Net Selling | Net Selling | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $113.87B | 253,718,831 | 91.40% | 1.51% | Net Selling | Net Selling | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $143.95M | 80,421,181 | 9.25% | 90.75% | Net Buying | Net Buying | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.31B | 192,114,344 | 93.36% | 1.73% | Net Selling | Net Selling | ||
| APLS | APELLIS PHARMACEUTICALS INC | $3.15B | 126,525,218 | 76.29% | 23.71% | Net Selling | Net Selling | ||
| HALO | HALOZYME THERAPEUTICS INC | $8.37B | 117,597,000 | 77.68% | 22.32% | Net Selling | Net Selling | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.12B | 57,596,358 | 76.19% | 23.81% | Net Selling | Net Selling | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.80B | 122,912,387 | 84.02% | 15.86% | Net Selling | Net Selling | ||
| REGN | REGENERON PHARMACEUTICALS INC | $80.22B | 105,099,464 | 68.27% | 31.73% | Net Selling | Net Selling | ||
| MDXG | MIMEDX GROUP INC | $937.49M | 148,102,159 | 46.43% | 53.57% | Net Buying | Net Selling | ||
| INVA | INNOVIVA INC | $1.50B | 74,769,062 | 60.33% | 39.67% | Net Selling | Net Buying | ||
| UTHR | UNITED THERAPEUTICS CORP | $21.08B | 43,056,599 | 86.71% | 13.29% | Net Selling | Net Selling | ||
| ACAD | ACADIA PHARMACEUTICALS INC | $4.42B | 169,181,817 | 72.19% | 27.81% | Net Selling | Net Selling | ||
| INCY | INCYTE CORP | $19.98B | 196,322,703 | 77.70% | 22.30% | Net Selling | Net Selling |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.